Dr. James Larrick is a biomedical entrepreneur with an international reputation in biotechnology [cytokines, therapeutic antibodies, molecular biology, pharmaceutical drug development] having written or co‑authored eight books, over 250 papers/chapters and>forty patents in his twenty-five year career. He has served on the editorial board of six journals. Dr. Larrick’s work on therapeutic antibodies and other protein therapeutics has spanned the whole range of biopharmaceutical product development from target discovery, process science to clinical trials.
Dr. Larrick received his MD and PhD. degrees from Duke University School of Medicine, Durham, NC as a Medical Scientist Training Program scholar. After house-staff training in the Department of Medicine at Stanford University School of Medicine, he completed a post‑doctoral fellowship in the Stanford Cancer Biology Research Labs working on therapeutic human monoclonal antibodies for cancer and infectious diseases. In 1982, he continued this work as a founding scientist of Cetus Immune Research Labs, Palo Alto, CA, where he became Director of Research in 1986. While at Cetus he pioneered the use of PCR for the construction of recombinant antibodies. This technology was critical to the development of antibody library cloning and the practical development of recombinant antibodies as a new class of biotherapeutics. Recent work at PRI has focused on Applied Healthspan Engineering--the utilization of advances in molecular medicine to preserve well-being as we age.
In 1991, Dr. Larrick founded PIMM, now called the Panorama Institute of Molecular Medicine, a non‑profit research institute situated near Stanford University and Panorama Research Inc., a biopharmaceutical incubator company. Dr. Larrick’s PRI team has discovered and initiated development of a diverse, and innovative portfolio of pharmaceutical molecules addressing major unmet needs in cancer, infectious, autoimmune, cardiovascular, neurological and metabolic diseases. PRI has incubated >20 life science projects. Based on this work he has co-founded more than a dozen companies. Among these are Planet Biotechnology Inc., Kalobios Inc., NuGen Technology Inc., Panolife Products Inc., PanResearch Inc., Adamas Inc., Absalus Inc. (now Teva Inc.), Humanyx Ltd., TransTarget Inc., Larix Bioscience LLC, and Galaxy Biotech LLC. Two companies have been co-founded in Europe, PanGenetics b.v. and TargetQuest b.v. To date PRI-initiated projects and/or companies have led to six IPOs/exits. Currently Dr. Larrick serves on the Boards of several early stage companies.
Since 1998 Dr. Larrick has led the biopharma screening committees of various Bay Area angel investment groups, most recently serving on the Board of Life Science Angels. Over the past 5 years Dr. Larrick has served as a managing director and Chief Medical Officer of Presidio Partners-funded Velocity Pharmaceutical Development LLC, based in South San Francisco.
Dr. Larrick has organized and led a number of biomedical expeditions, including studies of nutrition, malaria, genetics, and high altitude adaptation among native peoples of Ecuador, Peru, Guatemala, Nepal, India, Tibet and China. He has a genuine interest in fostering entrepreneurial activities and promoting healthcare among those less fortunate. Presently he helps fund and serves on the Boards of two non-profits, the Sustainable Sciences Institute (www.ssilink.org) focused on education and delivery of appropriate technology to less developed countries in Africa and Latin Americaand the Sankofa Center for African Dance and Culture focused on education, diagnosis and therapy of HIV/AIDS and tuberculosis in Ghana ( HYPERLINK "http://www.thesankofacenter.org/"www.thesankofacenter.org). Juvare is his latest effort to improve health among people in the South Omo Valley in Ethiopia, in Bhutan and on Komodo Island in Indonesia.